|

The Role of Adjuvant Radiotherapy in Mesothelioma Treatment

ByHolly Zink
The Role of Adjuvant Radiotherapy in Mesothelioma Treatment

A groundbreaking study explored a different approach to mesothelioma treatment. Patients treated with radiation therapy after surgery showed promising results. This technique is called adjuvant radiotherapy.

Revolutionizing Mesothelioma Treatment

Mesothelioma is a rare but aggressive type of cancer that affects the lining of the lungs, heart, or abdomen. It’s caused by exposure to asbestos, a harmful mineral that was once widely used in construction and manufacturing. Because it’s often diagnosed at an advanced stage, treatment options have been limited. And the prognosis hasn’t been very promising.

For a long time, the standard treatment for mesothelioma has been a combination. This often includes chemotherapy, surgery, and radiation therapy. Of all three, chemotherapy is the common approach. Only one chemotherapy drug combination is FDA approved for mesothelioma: pemetrexed with cisplatin.

Adjuvant Radiotherapy Shines in Mesothelioma Study

Recently, a groundbreaking study has been conducted to explore a different approach. In this study, patients were treated with radiation therapy after surgery. This is called adjuvant radiotherapy. This technique involves delivering radiation in fewer, more intense sessions. This process is known as accelerated hypofractionation.

The study, which began in 2017, enrolled 29 patients with mesothelioma. These patients were carefully chosen based on strict criteria. For example, not having received previous radiation therapy. They were then treated using a special radiation therapy system.

The early findings are encouraging. None of the patients experienced severe lung problems. About 65% of patients reported mild symptoms of pneumonitis, and 10% experienced some lung toxicity. Fortunately, these cases were manageable without a lot of medical intervention.

Aside from pneumonitis, about half of the patients reported mild coughing and shortness of breath.

The radiation doses used in this study were carefully controlled to minimize any harm to healthy lung tissue. The results show promise, but more research is needed. The study is ongoing, and scientists are eager to learn more about this new treatment approach’s long-term effects and benefits.

Source

Parisi E, Arpa D, Ghigi G, et al. Malignant pleural mesothelioma and radiotherapy: Lung toxicity results of an interim analysis in prospective pilot trial. Int J Radiat Oncol Biol Phys. 2023;117(2): e46. doi: 10.1016/j.ijrobp.2023.06.749. https://www.sciencedirect.com/science/article/pii/S0360301623051830

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…